GNH USA

Europe — EMA

Miglustat Accord

GNH USA supplies Miglustat Accord (Miglustat), a glucosylceramide synthase inhibitor for Gaucher disease type 1 and Niemann-Pick disease type C.

Miglustat

Request sourcing

1
Pack/s

What is Miglustat?

Miglustat, the active ingredient in Miglustat Accord, is a glucosylceramide synthase inhibitor presented as an oral tablet for oral use. It treats Gaucher disease type 1 and Niemann‑Pick disease type C in patients requiring substrate reduction therapy.

GNH USA supplies Miglustat Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Miglustat used for?

Miglustat is used as a substrate reduction therapy for lysosomal storage disorders, targeting the accumulation of glycosphingolipids.

- Gaucher disease type 1: reduces substrate buildup, improving hematologic parameters and organ size. - Niemann‑Pick disease type C: slows neurological decline and stabilises visceral disease. - Substrate reduction therapy: provides an oral option to lower glycosphingolipid synthesis in approved lysosomal storage conditions.

What are the side effects of Miglustat?

Miglustat may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Diarrhoea: frequent loose stools, often mild to moderate. - Nausea: sensation of unease or urge to vomit. - Abdominal pain: cramping or discomfort in the stomach area. - Weight loss: unintended reduction in body weight. - Flatulence: increased intestinal gas. - Taste alteration: changes in taste perception.

Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas, presenting with severe abdominal pain. - Severe hypersensitivity: rash, swelling, or anaphylactic reactions. - Elevated liver enzymes: potential indication of hepatic stress. - Severe depression or mood changes: may require psychiatric evaluation. - Seizures: rare neurologic events requiring immediate medical attention.

What precautions apply to Miglustat?

Before initiating therapy, several safety considerations should be observed.

- Monitor blood glucose: Miglustat can affect carbohydrate metabolism. - Assess liver function: periodic liver enzyme testing is recommended. - Evaluate gastrointestinal tolerance: patients should be advised to report persistent diarrhoea or abdominal pain. - Watch for mood changes: monitor for signs of depression or suicidal ideation. - Avoid in patients with known hypersensitivity to miglustat or excipients. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

What does Miglustat interact with?

Miglustat may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase miglustat exposure. - Strong CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic effect. - Co‑administration with other substrate reduction agents: risk of additive toxicity.

Moderate Interactions (Monitor Closely): - Antidiabetic drugs: miglustat can affect glucose control, dose adjustment may be needed. - Warfarin: potential alteration of INR, requiring closer monitoring. - Other gastrointestinal irritants: may exacerbate nausea or diarrhoea.

Frequently asked questions

What conditions is Miglustat Accord used to treat?+
Miglustat Accord is prescribed for Gaucher disease type 1 and Niemann‑Pick disease type C. In both conditions it acts as a substrate reduction therapy, lowering the accumulation of glycosphingolipids that cause organ enlargement, bone disease, and neurological decline.
How does miglustat work in the body?+
Miglustat blocks the enzyme glucosylceramide synthase, the first step in the synthesis of glycosphingolipids. By inhibiting this enzyme, the drug reduces the production of glucosylceramide and downstream lipids, decreasing their storage in lysosomes and helping to restore normal cellular function.
What is the usual dose of Miglustat Accord?+
The specific dose of Miglustat Accord is determined by the prescribing physician based on the patient’s age, weight, disease severity, and renal function. Healthcare professionals tailor the regimen to achieve optimal therapeutic effect while minimizing adverse reactions.
Is Miglustat Accord safe to use during pregnancy or breastfeeding?+
The safety of miglustat in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and clinicians usually weigh potential benefits against possible risks before prescribing to pregnant or nursing women.
How do I order Miglustat Accord from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does Miglustat compare with other treatments for these diseases?+
Miglustat offers an oral substrate reduction option, whereas alternatives such as enzyme replacement therapy (ERT) are administered intravenously. Miglustat can cross the blood‑brain barrier, providing potential benefit for neurological symptoms in Niemann‑Pick disease type C, a feature not shared by most ERT products.
What are the storage requirements for Miglustat Accord?+
Miglustat Accord should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct sunlight to maintain stability throughout its shelf life.
How is Miglustat Accord administered?+
Miglustat Accord is taken orally, usually with food to lessen gastrointestinal discomfort. The tablets are swallowed whole with a glass of water; they should not be crushed, chewed, or dissolved unless specifically instructed by a healthcare professional.
What are the most serious risks associated with Miglustat Accord?+
Serious adverse events include pancreatitis, severe hypersensitivity reactions, significant liver enzyme elevations, and rare neurological effects such as seizures. Patients should seek immediate medical attention if they experience severe abdominal pain, rash, jaundice, or unexplained neurological symptoms.
Who should not use Miglustat Accord?+
Miglustat Accord is contraindicated in individuals with known hypersensitivity to miglustat or any of its excipients. Caution is advised for patients with pre‑existing pancreatic disease, severe liver impairment, or uncontrolled diabetes, and it should be avoided in pregnant or nursing women unless clearly justified.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Miglustat
Route
Oral Use
Manufacturer
Accord Healthcare Limited
Origin
EU

Related products

Miglustat 100 mg/1

Miglustat 100 mg/1

Miglustat · 100 mg

Miglustat
CAPSULE
CoTherix, Inc.
USA
Zavesca 100 mg

Zavesca 100 mg

Miglustat · 100 MG

Zavesca
CAPSULE
JANSSEN INC
CANADA
Sandoz Miglustat 100 mg

Sandoz Miglustat 100 mg

Miglustat · 100 MG

Sandoz Miglustat
CAPSULE
SANDOZ CANADA INCORPORATED
CANADA
Miglustat Accord

Miglustat Accord

Miglustat

Accord Healthcare Polska Sp. Z O.O.
EU